KRAS and colorectal carcinoma: Our own group and others has recently shown that detection of concurrent KRAS and TP53 mutations, with an incidence of 5% to 20% in CRC patients, correlated with resistance to neoadjuvant chemoradiation therapy (CRT) in patients with rectal cancer [10]–[12].